We treated SJSA cells (osteosarcoma cells with amplifications of MDM2 and CKD4, cf. www.cbioportal.org and Fig. S1a) with combinations of the CDK4 inhibitor Palbociclib (PD0332991) and the MDM2 antagonist Nutlin. Here, CDK4 is linked to osteosarcoma.